全文获取类型
收费全文 | 3318篇 |
免费 | 219篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 104篇 |
妇产科学 | 65篇 |
基础医学 | 335篇 |
口腔科学 | 55篇 |
临床医学 | 330篇 |
内科学 | 804篇 |
皮肤病学 | 74篇 |
神经病学 | 273篇 |
特种医学 | 95篇 |
外科学 | 583篇 |
综合类 | 28篇 |
预防医学 | 212篇 |
眼科学 | 57篇 |
药学 | 200篇 |
中国医学 | 15篇 |
肿瘤学 | 303篇 |
出版年
2023年 | 41篇 |
2022年 | 61篇 |
2021年 | 115篇 |
2020年 | 60篇 |
2019年 | 79篇 |
2018年 | 94篇 |
2017年 | 64篇 |
2016年 | 93篇 |
2015年 | 74篇 |
2014年 | 103篇 |
2013年 | 141篇 |
2012年 | 180篇 |
2011年 | 214篇 |
2010年 | 100篇 |
2009年 | 95篇 |
2008年 | 142篇 |
2007年 | 168篇 |
2006年 | 132篇 |
2005年 | 121篇 |
2004年 | 127篇 |
2003年 | 114篇 |
2002年 | 111篇 |
2001年 | 75篇 |
2000年 | 78篇 |
1999年 | 61篇 |
1998年 | 26篇 |
1997年 | 19篇 |
1996年 | 19篇 |
1995年 | 26篇 |
1994年 | 15篇 |
1993年 | 14篇 |
1992年 | 76篇 |
1991年 | 56篇 |
1990年 | 59篇 |
1989年 | 67篇 |
1988年 | 66篇 |
1987年 | 68篇 |
1986年 | 63篇 |
1985年 | 52篇 |
1984年 | 37篇 |
1983年 | 22篇 |
1979年 | 31篇 |
1978年 | 14篇 |
1977年 | 16篇 |
1976年 | 15篇 |
1975年 | 14篇 |
1972年 | 15篇 |
1971年 | 18篇 |
1969年 | 13篇 |
1968年 | 13篇 |
排序方式: 共有3549条查询结果,搜索用时 671 毫秒
51.
Seyed Mostafa Nachvak Shima Moradi Javad Anjom-shoae Jamal Rahmani Morteza Nasiri Vahid Maleki Omid Sadeghi 《Journal of the Academy of Nutrition and Dietetics》2019,119(9):1483-1500.e17
ObjectiveWe conducted a systematic review and dose–response meta-analysis of prospective studies to summarize findings on the associations between intakes of soy, soy isoflavones, and soy protein and risk of mortality from all causes, cancers, and cardiovascular diseases.MethodsOnline databases were systematically searched to identify relevant articles published earlier than May 2018. We applied restricted cubic splines using random-effects analysis to assess dose–response associations. Between-study heterogeneity was assessed by I2 value and Cochrane Q test. Potential publication bias was assessed by visual inspection of funnel plots and Begg regression test.ResultsIn total, 23 prospective studies with an overall sample size of 330,826 participants were included in the current systematic review and the meta-analysis. Soy/soy products consumption was inversely associated with deaths from cancers (pooled relative risk 0.88, 95% CI 0.79 to 0.99; P=0.03; I2=47.1%, 95% CI 0.0% to 75.4%) and cardiovascular diseases (pooled effect size: 0.85, 95% CI 0.72 to 0.99; P=0.04; I2=50.0%, 95% CI 0.0% to 77.6%). Such significant associations were also observed for all-cause mortality in some subgroups of the included studies, particularly those with higher quality. In addition, higher intake of soy was associated with decreased risk of mortality from gastric, colorectal, and lung cancers as well as ischemic cardiovascular diseases. Participants in the highest category of dietary soy isoflavones intake had a 10% lower risk of all-cause mortality compared with those in the lowest category. We also found that a 10-mg/day increase in intake of soy isoflavones was associated with 7% and 9% decreased risk of mortality from all cancers and also breast cancer respectively. Furthermore, a 12% reduction in breast cancer death was indicated for each 5-g/day increase in consumption of soy protein. However, intake of soy protein was not significantly associated with all-cause and cardiovascular diseases mortality.ConclusionsSoy and its isoflavones may favorably influence risk of mortality. In addition, soy protein intake was associated with a decreased risk in the mortality of breast cancer. Our findings may support the current recommendations to increase intake of soy for greater longevity. 相似文献
52.
Hiroaki Shima Toshito Yasuda Takashi Hida Seiya Tsujinaka Kosho Togei Gen Nakamura Masashi Neo 《Foot and Ankle Surgery》2021,27(4):395-399
BackgroundHallux valgus (HV) is an important risk factor for falls (in older people); however, the detailed relationship is less understood. We aimed to evaluate postural stability in bilateral HV patients.MethodsTwo groups of 20 female patients—an HV group and a C (i.e., non-HV) group—participated in this study. Evaluations were made using the Timed Up and Go (TUG) test, the Berg Balance Scale (BBS), the Falls Efficacy Scale (FES), track length (LNG), velocity (VEL), enveloped area (ENV), and root mean square area (RMS).ResultsTUG and FES scores were significantly higher and BBS scores were lower in the HV group than in the C group. LNG was significantly longer, VEL was higher, and ENV and RMS were wider in the HV group than in the C group.ConclusionsThe HV group exhibited impaired walking mobility, balance, and postural stability. 相似文献
53.
Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction
Purpose
To evaluate the efficacy and safety of intense pulsed light (IPL) combined with meibomian gland expression (MGX) for treatment of refractory meibomian gland dysfunction (MGD).Methods
Ninety eyes of 45 patients were randomly assigned to receive either the combination of IPL and MGX or MGX alone (control). Each eye underwent eight treatment sessions at 3-week intervals. Parameters were evaluated before and during treatment as well as at 3–11 weeks after the last treatment session. Measured parameters included the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire score, noninvasive breakup time (NIBUT), fluorescein breakup time (BUT), lipid layer grade, lipid layer thickness (LLT), lid margin abnormalities, corneal and conjunctival fluorescein staining (CFS) score, meibum grade, and meiboscore.Results
A significant improvement in lipid layer grade was apparent in the IPL-MGX group from 6 to 32 weeks after treatment onset (adjusted P?<?0.001) but was not observed in the control group. The IPL-MGX group also showed significant improvements in LLT, NIBUT, BUT, lid margin abnormalities, and meibum grade compared with the control group at 24 and 32 weeks (adjusted P?<?0.001) as well as significant improvements in the SPEED score at 32 weeks (adjusted P?=?0.044) and in CFS score at 24 (adjusted P?=?0.015) and 32 (adjusted P?=?0.006) weeks.Conclusions
The combination of IPL and MGX improved homeostasis of the tear film and ameliorated ocular symptoms in patients with refractory MGD and is thus a promising modality for treatment of this condition. 相似文献54.
55.
56.
Hironori Tsujimoto Hiroyuki Horiguchi Risa Takahata Satoshi Ono Yoshihisa Yaguchi Shinsuke Nomura Nozomi Ito Manabu Harada Hiromi Nagata Yusuke Ishibashi Keita Kouzu Satoshi Tsuchiya Yujiro Itazaki Seiichiro Fujishima Yoji Kishi Hideki Ueno 《Journal of gastroenterology and hepatology》2020,35(5):788-794
57.
Risa Konishi Ryota Tanaka Sae Inoue Yuki Ichimura Toshifumi Nomura Naoko Okiyama 《The Journal of dermatology》2022,49(1):118-123
Dermatomyositis, an idiopathic inflammatory myopathy, is characterized by cutaneous itchy manifestations, which are frequently refractory and recurrent even after intensive immunosuppressive treatments. To evaluate the effectiveness and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in treating skin-dominant dermatomyositis in which myositis and interstitial lung disease are absent or in remission, we performed this prospective, single-arm, interventional study. A total of five Japanese patients (one male and four females, median [range] age, 64 [37–71] years) with refractory dermatomyositis-associated cutaneous manifestations were recruited and treated with a 12-week course of oral apremilast. Among five enrolled patients, three experienced diarrhea with full-dose apremilast (30 mg twice daily), two of whom withdrew from the study and recovered quickly afterwards. A total of three evaluable female patients (median [range] age, 65 [64–71] years) received apremilast treatment for 12 weeks. A 39.4% reduction from baseline Cutaneous Dermatomyositis Disease Area and Severity Index total activity score, but not the damage score, at week 12 was observed in all three patients. Visual analog scale of itching, and quality of life by Dermatology Life Quality Index were slightly improved in one and two apremilast-treated patients, respectively. As apremilast was effective, with expected and recoverable digestive adverse events (diarrhea), in patients with refractory and recurrent dermatomyositis-associated cutaneous manifestations in this first phase Ib study, it can be suggested as a possible treatment when aggressive immunosuppressive therapies with high-dose systemic corticosteroid and/or immunosuppressive agents for other manifestations, myositis, and interstitial lung disease, are not required. 相似文献
58.
59.
Koji Kimura Risa Takayanagi Haruko Yokoyama Yasuhiko Yamada 《Rheumatology international》2012,32(1):145-150
In Japan, the recommended dosage regimens of infliximab (IFX) for treatment of rheumatoid arthritis (RA) and Crohn’s disease
(CD) are different. However, the differences have not been analyzed theoretically. In a previous study, we constructed a pharmacokinetic–pharmacodynamic
model to investigate the effects of IFX for CD and found it useful to establish a rational dosage regimen of IFX for individual
patients with CD. In the present study, we investigated whether the theory-based model could be used for cases of RA and also
used it to evaluate the validity of the dosage regimen. The results obtained with our model were in good agreement with observed
tender joint count (TJC) ratio data, which was considered to show the validity of our analysis. Thus, we concluded that the
model could be used for patients with RA. Furthermore, a second administration of IFX given 2 weeks after the first infusion
was important to achieve remission in the early stage of RA. We also compared the estimated pharmacodynamic parameters of
RA with those of CD. The elimination rate constant of inflammation in RA was greater than that in CD, suggesting that the
recovery from inflammation in RA is faster than that in CD, and indicating a reason for the difference in dosage between RA
and CD. In conclusion, use of our model in light of the individual quantitative factor of tumor necrosis factor (TNF)-α allows
establishment of IFX dosage regimens for individual patients. 相似文献